Top 50 Biotechnology VC Funds & Investors in Israel (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Trendlines Group
VC Fund
|
19 | Israel, Singapore, United Kingdom | Seed, Series A | Health Care, Biotechnology, Medical Device | $650k–$15M |
|
Pontifax
VC Fund
|
16 | United States, Israel, France | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.3M–$128M |
|
Israel Innovation Authority
VC Fund
|
13 | Israel, United States, Mali | Grant, Seed, Pre-Seed | Health Care, Artificial Intelligence, Biotechnology | $140k–$5M |
|
OurCrowd
VC Fund
|
11 | Israel, United States, New Zealand | Series B, Series A, Seed | Software, Artificial Intelligence, Health Care | $604k–$65M |
|
aMoon Fund
VC Fund
|
7 | United States, Israel, France | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5.7M–$93M |
|
OrbiMed
VC Fund
|
7 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$151M |
|
Arkin Holdings
VC Fund
|
6 | Israel, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $2M–$95M |
|
ZORA Ventures
VC Fund
|
6 | Israel, United States, United Kingdom | Seed, Series A, Convertible Note | Biotechnology, Health Care, Internet | $1M–$8.1M |
|
Docor International Management
VC Fund
|
6 | Israel, United States | Series C, Series A | Health Care, Biotechnology, 3D Technology | $13M–$22M |
|
HBL Hadasit Bio Holdings
VC Fund
|
5 | Israel | Series A, Series B | Biotechnology, Medical, Health Care | |
|
Integra Holdings
VC Fund
|
4 | Israel | Seed, Series B, Series F | Biotechnology, Pharmaceutical, Life Science | |
|
Milk & Honey Ventures
VC Fund
|
4 | Israel | Seed, Pre-Seed, Series A | Biotechnology, Food and Beverage, Nutrition | $1.9M–$5.2M |
|
iAngels
VC Fund
|
4 | United States, Israel, United Kingdom | Seed, Series A | Software, Artificial Intelligence, Financial Services | $900k–$22M |
|
Cancer Focus Fund
VC Fund
|
4 | Israel, United States, Germany | Series A, Seed | Biotechnology, Medical, Health Care | $5.4M–$28M |
|
Takeda Ventures
VC Fund
|
4 | United States, United Kingdom, Israel | Series A, Series B | Biotechnology, Health Care, Therapeutics | $10M–$130M |
|
Welltech Ventures
VC Fund
|
4 | Israel, United States | Seed, Series A | Health Care, Artificial Intelligence, mHealth | $1.9M–$20M |
|
Consensus Business Group
VC Fund
|
4 | Israel, United States, United Kingdom | Seed, Series A | Health Care, Medical Device, Medical | $1M–$10M |
|
New York Ventures
VC Fund
|
4 | United States, Canada, Israel | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.5M–$53M |
|
Clal Biotechnology Industries
VC Fund
|
4 | Israel, United States | Series A, Series B | Health Care, Biotechnology, Medical | $4M–$55M |
|
Sapir Venture Partners
VC Fund
|
4 | Israel, United States, United Kingdom | Seed, Pre-Seed, Series A | Software, Biotechnology, Machine Learning | $1.3M–$40M |
|
Grove Ventures
VC Fund
|
4 | Israel, United States | Seed, Series A, Series B | Artificial Intelligence, Software, Machine Learning | $3.5M–$74M |
|
S2G Investments
VC Fund
|
4 | United States, Canada, Israel | Series A, Series B | Food and Beverage, Agriculture, Biotechnology | $4M–$100M |
|
Johnson & Johnson Robotics and Digital Solutions
VC Fund
|
4 | United States, Israel, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $300k–$100M |
|
GlenRock Israel
VC Fund
|
3 | Israel, United States | Seed, Series A, Series B | Software, Cyber Security, Health Care | $100k–$19M |
|
Office of the Chief Scientist
VC Fund
|
3 | Israel | Seed | Health Care, Biotechnology, Hardware | $500k–$1M |
|
Binder & Partners Ventures
VC Fund
|
3 | Israel, France, United States | Seed, Pre-Seed, Series A | Software, Information Technology, Computer | $2M–$14M |
|
EIT Food
VC Fund
|
3 | United Kingdom, Israel, Germany | Grant, Non-Equity Assistance, Seed | Biotechnology, Food and Beverage, AgTech | $1.2k–$11M |
|
SciSparc
VC Fund
|
3 | Israel | Corporate Round | Pharmaceutical, Cannabis, Biopharma | $400k–$700k |
|
fresh.fund
VC Fund
|
3 | Israel, United States, Norway | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $300k–$21M |
|
Nevateam Partners
VC Fund
|
3 | Israel | Seed, Series A | AgTech, SaaS, Farming | $5M–$10M |
|
DSM Venturing
VC Fund
|
3 | United States, Canada, Israel | Series A, Series B | Biotechnology, Health Care, Manufacturing | $3.5M–$32M |
|
Siddhi Capital
VC Fund
|
3 | United States, Israel, Canada | Seed, Series A, Pre-Seed | Food and Beverage, Biotechnology, Nutrition | $1M–$21M |
|
FutuRx
VC Fund
|
3 | Israel | Seed | Biotechnology, Life Science, Biopharma | |
|
Ziegler Meditech Equity Partners
VC Fund
|
3 | United States, Israel | Series C, Series E, Series F | Health Care, Biotechnology, Mobile | |
|
Millenium Food-Tech
VC Fund
|
3 | Israel | Seed, Series A, Convertible Note | Food and Beverage, Manufacturing, Retail | $2.5M–$15M |
|
Accelmed
VC Fund
|
3 | Israel, United States | Series D, Series A | Health Care, Medical Device, Medical | $695k–$96M |
|
Pitango VC
VC Fund
|
3 | Israel, United States, China | Series A, Series B, Series C | Software, Health Care, Information Technology | $4M–$100M |
|
RMGP Biopharma Investment Fund
VC Fund
|
2 | Israel | Seed, Series B | Biotechnology, Biopharma, Health Care | |
|
Bits x Bites
VC Fund
|
2 | China, Israel, Singapore | Series A, Seed, Series B | Biotechnology, Food and Beverage, Food Processing | $4k–$347M |
|
Bridges Israel
VC Fund
|
2 | Israel, United States, United Kingdom | Series A, Series B | Agriculture, Health Care, Internet of Things | $2.2M–$60M |
|
Impact First Investments
VC Fund
|
2 | Israel, United States | Seed, Series A | Health Care, mHealth, Medical Device | $500k–$8M |
|
Ocean Azul Partners
VC Fund
|
2 | United States, Israel, Australia | Seed, Series A | Software, Information Technology, Artificial Intelligence | $1M–$14M |
|
M Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Tyson Ventures
VC Fund
|
2 | United States, Israel | Grant, Series A | Food and Beverage, Biotechnology, Software | $4M–$37M |
|
CE Ventures (CEIIF)
VC Fund
|
2 | Israel, United States, India | Series B, Series A, Series C | Software, Analytics, Big Data | $4M–$40M |
|
Arancia International
VC Fund
|
2 | Israel, United States, Malaysia | Series A, Series B | Health Care, Biotechnology, Life Science | |
|
PeakBridge
VC Fund
|
2 | Israel, United States, United Kingdom | Series A, Seed, Series B | Food and Beverage, Health Care, Food Processing | $571k–$50M |
|
Flerie Invest
VC Fund
|
2 | Sweden, Israel, Iceland | Series A, Series B | Biotechnology, Health Care, Medical | |
|
Yozma Group
VC Fund
|
2 | Israel, United States, Australia | Series B, Seed | Health Care, Medical, Software | |
|
Pfizer
VC Fund
|
2 | United States, Israel, France | Post-IPO Equity, Series A, Corporate Round | Biotechnology, Health Care, Pharmaceutical | |
| Access all 628 VC funds in Israel Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A
- Geography: Israel, Singapore, United Kingdom
Investor stats
- Total investments: 69
- Round size: Seed $650k–$4.1M; Series A $2.3M–$15M
- Lead/follow: 20% lead, 80% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- IBI-Ag — IBI-Ag is a biotechnology company developing a new class of bioinsecticides. IBI-Ag is focused on the discovery and development of new types of biological solutions that utilize environmentally friendly technology to control insects. IBI-Ag utilizes breakthrough technology to produce efficient, selective, and safe bio-insect control solutions.IBI-Ag technology is highly cost-effective due to its fermentation suitability enabling farmers to produce agricultural produce at a low cost.
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Arcuro Medical — Arcuro develops a new repair system for meniscus tears of the knee. Arcuro’s proprietary SuperBall repair system consists of a knotless, all-suture anchor and innovative delivery system. The company was founded in 2013.
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 113
- Round size: Series A $6.3M–$110M; Series B $20M–$128M; Series C $12M–$101M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $14M in 2020
Portfolio highlights
- ArQule — ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).
- Graviton Bioscience — Curing Disease through Restored Homeostasis
- Applied Immune Technologies — Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications inpathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.
The Israel Innovation Agency, the Innovation Authority, was established in 1965 as the Office of the Chief Scientist of the Ministry of Industry and Trade and was designed as a body that supports R & D conducted in the framework of government research institutes. Industrial development in order to increase industrial exports of high-techproducts. The Chief Scientist focused on reducing the risk by participating in financing the project, which the private companies chose and led.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Biotechnology
- Stage:Grant, Seed, Pre-Seed
- Geography: Israel, United States, Mali
Investor stats
- Total investments: 183
- Round size: Seed $500k–$5M; Grant $140k–$3.5M; Pre-Seed $150k–$2.1M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Q-Factor —
- GeoRank Studio — GeoRank Studio is a specialist SEO, Generative Engine Optimisation (GEO), and Reputation Management agency helping businesses across the UK, EU, and US gain visibility in both traditional and AI-powered search.As AI search engines including ChatGPT, Perplexity, and Google AI Overviews now answer a growing share of commercial queries without aclick, GeoRank Studio helps businesses adapt. We implement the technical and content changes needed to get brands cited in AI-generated answers — a discipline known as Generative Engine Optimisation or GEO.Our core services include technical SEO audits and full implementation, GEO optimisation including FAQPage schema markup, entity optimisation, and AI crawler configuration, reputation management including review removal from Google and Trustpilot, negative SERP suppression, and monthly AI citation tracking reports.GeoRank Studio was founded in 2022 and operates fully remotely, serving clients in professional services, SaaS, hospitality, luxury retail, and e-commerce. All packages include a 14-day money-back guarantee.Official Website: georankstudio.com
- Inspira Technologies — Inspira Technologies is an innovative Medical Technology Company focused on the acute respiratory care market. The ART, Inspira’s novel technology, can address the unmet need of providing acute respiratory treatment that prevents mechanical ventilation while patients are awake and breathing spontaneously.
Invest in exclusive and pre-vetted startups, late-stage companies, and top tier funds - private market access made simple, transparent, and institutional-grade.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series B, Series A, Seed
- Geography: Israel, United States, New Zealand
Investor stats
- Total investments: 286
- Round size: Seed $604k–$10M; Series A $5.3M–$22M; Series B $7M–$65M
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Oriient — Bringing the GPS revolution indoors with the most scalable and accessible solution for buildings. No Hardware, Cost Effective, and Highly Accurate.
- Sequentify — Sequentify provides a technology that is based on tools from the synthetic biology and AI software worlds for targeted DNA sequencing applications such as cancer diagnostics, carrier screening, COVID-19 surveillance and other applications.
- BetterSeeds — The company focuses on non-GMO genome editing using CRISPR-Cas9 for creating a novel breed of seeds and crop traits that address the 21st-century agriculture challenges. BetterSeeds provides advanced seeds enabling better crops for mechanized harvesting, extreme e climate resistance, higher calory and nutrient values, and more.
aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science toaccelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 77
- Round size: Series A $5.7M–$83M; Series B $22M–$93M; Series C $30M–$82M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
- Lin Health — Online chronic pain recovery program designed to get you back to the life you want to live. One-on-one coaching. Real pain reduction results.
- Connie Health — At Connie Health, our Medicare advisors help older Americans find the right Medicare plan - all at no cost to you.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 611
- Round size: Series A $10M–$140M; Series B $24M–$151M; Series C $15M–$131M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- MDClone — The MDClone ADAMS Platform is a self-service, data analytics environment powering healthcare collaboration, innovation, and data-driven projects.
- Beijing Tianxing — Beijing Tianxing is a clinical solutions company for sports medicine for implants, arthroscopy devices, and sports medicine equipment.
- Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology
Explore Arkin Capital: A leading multi-asset manager driving strategic investments across health, technology, equity, real estate and more
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: Israel, United States, Switzerland
Investor stats
- Total investments: 31
- Round size: Seed $2M–$6M; Series A $15M–$29M; Series B $23M–$95M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $270M in 2021
Portfolio highlights
- Lendbuzz — Lendbuzz is an AI-based auto finance platform that helps consumers with thin or no credit history obtain financing when purchasing a car. Powered by machine learning and proprietary algorithms, Lendbuzz is able to better assess the creditworthiness of consumers with limited credit history, who are underserved by the traditional banks. By partneringwith auto dealerships, Lendbuzz is able to offer consumers attractive financing solutions and dealerships are able to close additional business opportunities and serve a more diversified client base. Lendbuzz is headquartered in Boston, Massachusetts and was founded in 2015.
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Nocion Therapeutics — Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation.
Impact investing in Israeli technology. ZORA is an impact investing fund investing in early-stage Israeli companies solving global challenges in health, education, economic inclusion and the environment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Internet
- Stage:Seed, Series A, Convertible Note
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 14
- Round size: Seed $1M–$7M; Series A $4M–$8.1M
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Newmoo — Newmoo makes plant-based cheeses and dairy alternatives.
- WeedOut — WeedOut: Exploiting Sterility against Resistant Weeds
- Forsea Foods — Forsea Foods develops cell-cultured seafood through the use of patented organoid technology which allows them to bypass the scaffolding stage of cultivated meat production.
Docor International B.V. is a fully-owned subsidiary of Crecor B.V. Both Docor and Crecor were formed as wholly-owned subsidiaries of the Van Leer Group Foundation to promote and participate in commercial activities in Israel.
Show more...Investment focus
- Industry: Health Care, Biotechnology, 3D Technology
- Stage:Series C, Series A
- Geography: Israel, United States
Investor stats
- Total investments: 14
- Round size: Series C $13M–$22M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Check-Cap — Check-Cap Ltd. is merging with MBody AI to create a leading publicly traded embodied AI company powering autonomous workforces.
- Ocon Healthcare — OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.In addition to our flagshipproduct, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.
- Raziel Health — Raziel Health’s mission is to bring world-class, disruptively less expensive healthcare to everyone, in the comfort of their home. Its unique, integrated system combines easy-to-use technologies that support positive patient experience, enable timely clinical intervention, and meet individual patient goals while using data analytics to supportwellness and disease management.
Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B
- Geography: Israel
Investor stats
- Total investments: 9
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- ProtAb — ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for thetreatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
- KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
- Enlivex Therapeutics — Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn'sDisease, and other autoimmune and inflammatory disorders.The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Our expert team is the first to examine and evaluate the Hebrew University's biomedical breakthroughs. We then capitalize decades of experience - transforming the inventions into pioneering companies. Our golden eggs Ayana Pharma A late stage company with
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Life Science
- Stage:Seed, Series B, Series F
- Geography: Israel
Investor stats
- Total investments: 8
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- BacoCure — BacoCure is developing a novel bacterial product for local therapy of non-muscle invasive bladder cancer (NMIBC) patients.
- Splisense — Transformative RNA Based Treatments -Antisense Oligonucleotides- Targeting the Root Cause of Pulmonary Diseases Our innovative RNA based therapies, based on Antisense Oligonucleotides (ASOs), restore and modify protein functionality, addressing untreatable pulmonary diseases.
- Rebiotic Rx — Develops nanotechnology-based antibiotics with the focus on resistant bacteria
Tel-Aviv based investment firm, focused on the effective acceleration of disruptive New Protein technologies
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Nutrition
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel
Investor stats
- Total investments: 5
- Round size: Seed $3.5M–$5.2M; Pre-Seed $1.9M–$2.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- PoLoPo — PoLoPo is a biotech company that produces proteins on a large scale and according to specifications. PoLoPo develops a "superAA" plant by employing directed metabolic engineering techniques and fully utilizing plants' capacity as various metabolite and green protein factories. A significant amount of free amino acids can be producedby the superAA. The increased production of amino acids is then translated into an increase in the scale at which proteins are produced in plant organs.
- SuperMeat — SuperMeat is an Israeli bio-tech and food-tech company, developing a technology to create clean meat from chicken cells in a safe and controlled environment, external to the animal’s body. SuperMeat is set to revolutionize the meat industry from its core, aspiring to secure a better future for humans and animals alike. Clean meat is grown in acontrolled, sterile environment without the use of antibiotics and without any possibility of fecal contamination, such as salmonella. Clean meat will require significantly less resources for its production (99% less land, 90% less water), making it both a healthy and sustainable food source for the coming century.
- Meala Foodtech — Revolutionary texturized plant proteins that replace eggs and hydrocolloids. Clean-label, allergen-free solutions for baking, savory foods, and dressings.
Invest in groundbreaking startups with iAngels. Discovercutting-edge technology and join a community of forward-thinking investors shapingthe future of entrepreneurship.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Financial Services
- Stage:Seed, Series A
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 132
- Round size: Seed $900k–$10M; Series A $4.5M–$22M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely still investing — raised $56M in 2021
Portfolio highlights
- Nas Daily —
- ActiveLens — ActiveLens turns your meeting recordings and voice messages into automated workflows across your business tools- without the AI garbage. Admins customize workflows with a no-code builder, then the step-by-step wizard does 95% of the work while letting you review and modify every data point before it enters your systems. Connect via pre-builtintegrations (Salesforce, Monday, HubSpot, Jira, Trello) or easily connect any system with an API. Assign steps to the right team members and maintain complete visibility from voice to execution.
- Recapp —
Cancer Focus Fund is an oncology-focused investment firm advancing breakthrough cancer therapies by partnering with leading scientists, institutions and early-stage companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: Israel, United States, Germany
Investor stats
- Total investments: 10
- Round size: Series A $5.4M–$28M
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — raised $50M in 2019
Portfolio highlights
- KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
- Starget Pharma — Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues.
- Nectin Therapeutics — NectinTX develops next-generation delivery platforms for immuno-oncology and precision therapeutics. Discover breakthrough protein expression technologies that power safer, more effective treatments.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 104
- Round size: Series A $10M–$58M; Series B $20M–$130M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
- Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Welltech Ventures is Israel’s leading fund focused exclusively on investing in the health and wellness space. We seek to partner with entrepreneurs who epitomize the Startup Nation’s ethos and are building paradigm-shattering companies that are making an impact in the wellness space. As thought leaders we work with global investors focused onaccessing and investing in the Israeli tech ecosystem’s most promising entrepreneurs.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, mHealth
- Stage:Seed, Series A
- Geography: Israel, United States
Investor stats
- Total investments: 17
- Round size: Seed $1.9M–$19M; Series A $6M–$20M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- MDI Health — Transform Quality Metrics Clinical Outcomes & Costs all inOne Platform. Your AI Co-Pilot for Medication Management
- Antidote Health — AntidoteHealth.ai offers primary care on its telehealth app on a 24/7 basis, including prescriptions & more. Book your appointment today!
- Helping Hand —
Acting as advisor to companies within the Tchenguiz Family Trust, Consensus Business Group has amassed a portfolio of over 300,000 residential freeholds worth over £4 billion and a commercial portfolio worth over £2 billion.Consensus Business Group has vast experience and a proven track record of acquiring stock directly from nationalhousebuilders and developers over 20 years.As a result of their strategic investment, Consensus Business Group is believed to be the largest owner and asset manager of residential freehold interests in the UK, representing in excess of 1% of the housing stock in England and 1.2% in Greater London.Their decisions are not subject to procrastinated board approval or credit committees and as a result they are able to perform quickly and consistently. They are not dependent on debt finance and they have immediate cash availability.Consensus Business Group prides itself on having the market knowledge and expertise to stand out from its competitors, and it is their diligent and efficient acquisition practices that ensure swift transactions.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Seed, Series A
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 22
- Round size: Seed $1.7M–$4.5M; Series A $1M–$10M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- IBI-Ag — IBI-Ag is a biotechnology company developing a new class of bioinsecticides. IBI-Ag is focused on the discovery and development of new types of biological solutions that utilize environmentally friendly technology to control insects. IBI-Ag utilizes breakthrough technology to produce efficient, selective, and safe bio-insect control solutions.IBI-Ag technology is highly cost-effective due to its fermentation suitability enabling farmers to produce agricultural produce at a low cost.
- MEDX Xelerator — MEDX Xelerator is a unique medical device and digital health incubator. It was founded by MEDX Ventures Group, together with three partners: Boston Scientific, Intellectual Ventures’ Invention Science Fund and Sheba Medical Center. Each of MEDX Xelerator’s partners contributes outstanding core competencies, which complement one another and togethercreate a solid foundation for your success. Our incubator is seeking medical innovations for minimally invasive procedures, medical robotics, medical implants and digital health.Our vision is to leverage the power of MEDX Xelerator, and together with the extraordinary Israeli med tech innovation scene create a local cluster of entrepreneurial companies with breakthrough solutions to true unmet medical needs. Our mission is to nurture those promising technologies into successful medical ventures for the benefit of patients and health care professionals. We see you, the entrepreneur, as the key to success and we are here for you to make it happen.
- Synchrony Medical — Synchrony Medical is a clinical stage medical device company developing LibAirty, a next generation, home-use, airway clearance system designed to help patients with chronic lung disease such as COPD and CF maintain clear lungs with a short, daily, proficient treatment.
New York Ventures is dedicated to encouraging innovation and fueling economic growth in communities across the State. This venture capital investment arm of Empire State Development is one of New York State's business resources and innovation investments, including the Governor's START-UP NY program, Innovation Hot Spots, the RegionalEconomic Development Councils, the Centers of Advanced Technology and Centers of Excellence networks, and the SUNY 2020 Initiative.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 127
- Round size: Seed $1.5M–$7M; Series A $3M–$20M; Series B $2.5M–$53M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Adro — Designed to work when you arrive Spend and save like a local. Easy to use. No unfair fees.
- BQP — BosonQ Psi Pvt. Ltd. (BQP) is a state-of-the-art SaaS-based enterprise software venture leveraging the power of Quantum computing to speed up virtual simulations of Multiphysics and Computer-Aided Engineering (CAE) nature. BosonQ Psi is at the forefront of this quantum revolution. Our vision is to become the premier multiphysics simulation softwareusing quantum computing. Our world-class software suite will include computational science fields of fluid dynamics, structural dynamics, thermal, chemical, and aeroacoustics. With such an innovative product, we will revolutionize the computational world by enabling high-fidelity simulations that are impossible to solve with current computing technology. Further, this product will aid aerospace, automotive, energy, manufacturing, biotechnology, civil engineering, and astrophysics industries in saving millions of dollars by reducing long turnaround times of simulations used in the design process and give higher accuracy to make significant design changes for giving rise to the next generation of an electric car, eVTOL, skyscraper, or even Mars Rover.The possibility to harness the power of quantum computers is endless, and we at BQP thrive on pushing the boundaries of quantum computing technologies to serve our clients. We have made it our mission to bring these possibilities into the hands of every person - from a researcher to a scientist, from a professor to a student. Our name, BosonQ Psi, pays tribute to the great Indian physicist Dr. Satyendra Nath Bose, after whose name the elementary particle in quantum mechanics, Boson, was named and further incorporates the fundamental quantity that describes the state of the quantum particle - Psi, thus symbolizing the company's fundamental goal to contribute in India's goal to be the leader in the Quantum realm and also become a global leader in Quantum paradigm shift in coming years.
- CryoBio — CryoBio is an agricultural biotech company that provides biological solutions that allow crops to withstand sub-zero temperatures without damage.
Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI).
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 15
- Round size: Series A $4M–$55M; Series B $15M–$33M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- TytoCare — TytoCare offers the Home Smart Clinic - for accessible, high-quality primary care from home, with no compromises.
- Sight Diagnostics — Combining AI and breakthrough hardware to bring lab-quality CBC results to the doctor's office.
- Cadent Therapeutics — Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, andnovel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.It was founded in 2010 and headquartered in Cambridge, Massachusetts.
Early Stage VC
Show more...Investment focus
- Industry: Software, Biotechnology, Machine Learning
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 20
- Round size: Seed $1.3M–$10M; Series A $10M–$40M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
- Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
- DeepCure — DeepCure is a Boston-based therapeutics company that harnesses advanced AI, physics-based tools and automation to discover novel small molecules for challenging targets. DeepCure currently has a lead asset in IND-enabling studies and other programs focused on drugging intractable targets that have t
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Grove Ventures is a leading early-stage venture capital fund in Israel. It partners early with exceptional Israeli founders who believe th...
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 71
- Round size: Seed $3.5M–$20M; Series A $8M–$50M; Series B $20M–$74M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $185M in 2022
Portfolio highlights
- NoTraffic — NoTraffic has developed the first AI-powered traffic signal platform that connects road...
- LimitlessCNC — Limitless CNC is an AI-powered technology intended to improve CNC machining operations. It offers an AI CAM agent that works with NX-CAM to give industry-specific strategies and operations.
- Scala Biodesign — At Scala Biodesign, we provide our partners a unique one-shot computational protein design solutions to dramatically increase the value and accelerate the development of proteins into commercial products.
S2G Ventures is is a multi-stage venture fund investing in food and agriculture. We're harnessing the power of food innovation to create better outcomes for people and the planet.
Show more...Investment focus
- Industry: Food and Beverage, Agriculture, Biotechnology
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 203
- Round size: Series A $4M–$40M; Series B $5.9M–$100M
- Lead/follow: 48% lead, 52% follow
Portfolio highlights
- Atomo Coffee — Atomo Coffee is a developer of molecular coffee. Atomo has reversed engineered the coffee bean to create a smooth cup of coffee, made of naturally derived ingredients, and more sustainable than current commercial coffee.
- Common Energy — Save Money Each Month. Use Clean Energy.
- Big Bold Health — Big Bold Health® is a platform company providing immune health solutions through nature's wisdom and modern science.
Healthcare innovation wherever it originates.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 73
- Round size: Series A $5.9M–$63M; Series B $18M–$55M; Series C $300k–$100M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Moon Surgical — Create the OR of the future, one that is sustainable, efficient, and digitalized.
- Manus Neurodynamica — Manus Neurodynamica is a triage device to support early diagnostics in Parkinson's disease.
- Glyphic Biotechnologies — We sequence proteins. We have exciting updates coming soon... Contact us or sign up for updates below to be the first to know. Let's Chat. Partner. Collaborate. Team Up. Discuss. Talk. Co-Develop. Let's build something great and change the future of proteomics together. Send us a message! Subscribe to our updates!
A Private Equity Investment Company Founded by Leon Recanati in 2003, GlenRock leverages a unique combination of private equity, multidisciplinary in-house expertise, unmatched access to quality dealflow, and a focused but flexible investment strategy to achieve maximum returns.
Show more...Investment focus
- Industry: Software, Cyber Security, Health Care
- Stage:Seed, Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 33
- Round size: Seed $1M–$19M; Series A $1.5M–$9M; Series B $100k–$12M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Constru — Constru offers a breakthrough computer vision technology to superpower the engineering and project management teams onsite, monitoring every job, on every wall, throughout the construction process. The system collects and analyses photographic data and generates prescriptive insights to support business decisions and help the teams reliably delivertop-quality projects on time and on budget.
- Treetoscope — The first and only commercial device that senses the internal water flow of a plant and directly measures its water consumption and real-time irrigation needs. without extrapolations based on indirect sensing technologies.Treetoscope offers a SaaS irrigation management platform, based on direct plant sensing technology. We tackle one of the mostcrucial challenges farmers face today: water scarcity and irrigation optimization. Our groundbreaking ag-tech enables the unprecedented measurement of real-time actual water use of trees (based on our patented single probe Sap Flow sensor). Through the Treetoscope solution, growers gain great value as a result of the affordability, scalability, and ease of deployment of our technology.
- MSICS Pharma — MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for medical purpose.
The Office of the Chief Scientist [OCS] in the Ministry of Economy is charged with execution of government policy for support of industrial R&D. The goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel’sscientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally. A variety of ongoing support programs developed and offered by the OCS play a major role in enabling Israel to be a key center for high tech entrepreneurship.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Hardware
- Stage:Seed
- Geography: Israel
Investor stats
- Total investments: 4
- Round size: Seed $500k–$1M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- LapSpace — LapSpace Medical was founded in 2011. It operates within the framework of the Misgav Venture Accelerator, part of The Trendines Group. The LapSpace team combines strong business and medical experience and knowledge.
- Sqwik - powered by Geev.Me.Tech LTD — Sqwik is a new way to create, join & follow fun activities, with new friends, within 3 hours.
- Digma Medical — Digma Medical | DiaGone - safe, one-time, 30 minute, minimaly-invasive, GI procedure for Restoring Glycemic Control for T2DM & NASH patients | No Implant
Binder & Partners Ventures is the investments' capital arm of Binder & Partners multi-family office. The ambition of BPV is to connect our investors with the most promising startup companies.
Show more...Investment focus
- Industry: Software, Information Technology, Computer
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, France, United States
Investor stats
- Total investments: 16
- Round size: Seed $2M–$5M; Series A $8M–$14M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Acsense — The enterprise IAM Resilience Platform offering backup and recovery to reduce the risk of downtime, maintain data integrity, and deliver seamless access.
- CYREBRO — CYREBRO is your online centralized interactive SOC platform that integrates all your security events with strategic monitoring, threat intelligence and IR
- Lumen — Lumen is a device and app that measures your metabolism in a single breath and provides daily personalized nutrition based on your metabolic data. Through the device and app, you can achieve your fitness goals whether they be weight loss, performance optimization, or simply improving your metabolic health.As a company, we are a team ofscientists, researchers, engineers, and designers, aimed at improving the way people understand their metabolism. We believe that a healthy metabolism is a key to better health and that everyone can attain it with a little help from Lumen.At Lumen, we are all about teamwork, friendship, and family. Curious about joining? We are always looking for creative people who share our passion for health and fitness to join our team.
EIT Food is a European Knowledge and Innovation Community (KIC), which was set up to transform our food ecosystem. By connecting consumers with businesses, start-ups, researchers and students from around Europe, EIT Food supports innovative and economically sustainable initiatives which improve our health, our access to quality food, and our environment
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, AgTech
- Stage:Grant, Non-Equity Assistance, Seed
- Geography: United Kingdom, Israel, Germany
Investor stats
- Total investments: 117
- Round size: Seed $226k–$11M; Grant $23k–$531k; Non-Equity Assistance $1.2k–$32k
- Lead/follow: 66% lead, 34% follow
Portfolio highlights
- constellr — Smart Farming and Climate Monitoring from Space. At constellr, we are using cutting-edge beyond-visual imaging technology to revolutionise the way we assess crucial aspects of our planet's health.
- Hooked Foods — Leading the transition to a harmless seafood system by serving healthy vegan seafood for everybody to truly enjoy.
- Óir na Farraige — Óir na Farraige aims to create a scalable seaweed farming system in Irish waters, offering a sustainable alternative to wild-harvested seaweed for biostimulant manufacturing.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based ontetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.
Show more...Investment focus
- Industry: Pharmaceutical, Cannabis, Biopharma
- Stage:Corporate Round
- Geography: Israel
Investor stats
- Total investments: 4
- Round size: Corporate Round $400k–$700k
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- LaraPharm — LaraPharm Ltd. is a group of people joined together by the belief that active components found in the Cannabis plant can provide a real answer to hundreds of types of disease currently not addressed at all, or poorly addressed.
- AutoMax Motors — AutoMax Motors is a vehicle importer company. It involved in the parallel importation and selling of various private automobile products.
- MitoCareX Bio — MitoCareX Bio is a biotechnology company that focuses on the discovery and development of drugs for cancers & other life-threatening diseases.
fresh.fund is an Israeli pre-seed venture capital fund investing in early-stage startups across segments and verticals.We're built to partner with early-stage founders from day one, often as the company's first institutional investors. Our model is refreshingly simple: up to $300,000 in pre-seed funding within <4 weeks and follow-oncapital as necessary.Check out our portfolio here >> https://www.fresh.fund/portfolio. It's never too early to have a conversation about your startup.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, Norway
Investor stats
- Total investments: 42
- Round size: Seed $2.2M–$12M; Pre-Seed $300k–$6M; Series A $11M–$21M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Wisio — Wisio lets social media creators and experts answer questions and requests from followers via paid interactions. The company’s platform empowers followers to gain exclusive access via personalized videos to their favorite creators. Wisio's flexible and easy-to-use platform is packed with features to help creators build deeper communitieswhile monetizing the creator - follower relationship. Thousands of them are already using it to help build their online reputation and business.Wisio's vision is to make everyone reachable.
- CopilotKit — CopilotKit is the full-stack framework for building user interactive agents and copilots. The company behind the AG-UI Protocol.
- Shifters AI — Shifters AI is a software company that develops artificial intelligence and robotic solutions.
NevaTeam Partners is an Agri-Food Tech ESG Impact driven Fund with world-class knowledge and expertise that specializes in identifying and investing in cutting-edge companies and technologies, contributing to the streamlining and increase in world food production in a sustainable way.
Show more...Investment focus
- Industry: AgTech, SaaS, Farming
- Stage:Seed, Series A
- Geography: Israel
Investor stats
- Total investments: 5
- Round size: Seed $5M–$10M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Brevel — Brevel developed a disruptive cultivation technology for sustainable, low cost and high quality production of microalgae for various yet untapped markets. The technology is based on high-tech indoor, sterile and fully automated systems which are illuminated from within at high intensity. The technology enables the surprising results of more than90% cost reduction and up to 200 higher yields compared to current alternatives. Brevel is using the advantageous production capabilities to enter multiple markets where microalgae derived products are needed.
- Clarifruit — First automated fruit and vegetable fresh produce quality control software solution by Clarifresh. Optimize your fresh produce QC >>
- Edete Precision Technologies for Agriculture — edete Precision Agriculture Technologies is solving the world’s ever-growing pollination challenge by developing and manufacturing an efficient, automated fruit orchard pollination system and providing optimized pollination services to companies and growers.By reducing the dependency on haphazard, insect-based pollination processes, edete’scontrolled and manageable mechanical pollination system improves the quantity and quality of fruit orchard yields.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 92
- Round size: Series A $3.5M–$32M; Series B $4.1M–$30M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Athian — Funding livestock sustainability via a connected carbon marketplace.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Phynova Group — Phynova is a British life science company that develops and commercialises natural healthcare products derived from active compounds found in plants. Founded in 2002, Phynova is an innovative life science company based in Oxford, UK with a subsidiary research company located in Beijing, China. Phynova develops and commercialises natural healthcareproducts derived from active compounds found in plants. Phynova develops products for use in global healthcare and FMCG markets. It identifies active ingredients from plants with a rich history of use in traditional medicine, especially in China, and develops solutions for global health concerns.
Siddhi Capital is the growth equity partner for convention-crushing food and beverage companies.
Show more...Investment focus
- Industry: Food and Beverage, Biotechnology, Nutrition
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Israel, Canada
Investor stats
- Total investments: 57
- Round size: Seed $1.7M–$6.3M; Pre-Seed $1M–$3.6M; Series A $5M–$21M
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- BlueNalu — BlueNalu's mission is to be the global leader in cellular aquaculture, providing consumers with great tasting, healthy, safe, and trusted seafood products that support the sustainability and diversity of our oceans.
- Nopalera — Vegan, cruelty free, and Latina owned. Handmade cactus products that celebrate culture and resilience.
- Jesse & Ben’s — Ben and Jesse think that people should be able to enjoy their favorite cuisine without the junk. Despite being the fastest-growing french fry brand in the nation, Jesse & Ben's still has a long way to go
FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.
Show more...Investment focus
- Industry: Biotechnology, Life Science, Biopharma
- Stage:Seed
- Geography: Israel
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Ramino Bio — Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around.
- Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
- Bsense Bio Therapeutics — Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders. Bsense pioneers a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, to achieve greater efficacy and safety.
Ziegler is a privately held investment bank, capital markets and proprietary investments firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Mobile
- Stage:Series C, Series E, Series F
- Geography: United States, Israel
Investor stats
- Total investments: 6
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Aposense — Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel.
- MAKO Surgical — MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specificosteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment.In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal.MAKO Surgical was founded in 2004 and is headquartered in Florida, USA.
- MobileAccess Networks — Corning Everon Network Solutions offer in-building cellular solutions to meet a broad array of design scenarios and mitigate RF propagation challenges.
Millennium Food-Tech is an R&D partnership traded on the Tel Aviv Stock Exchange that specializes in investment in and betterment of companies in food-tech sectors,. Millennium seeks to invest in companies that specialize in identifying and developing innovative, and transformative ideas in the food, drinks, and nutrition industry. Millenniumhas experienced management, proven solutions, and a supportive network to develop ideas and start-ups from early-stage to maturity to exit.
Show more...Investment focus
- Industry: Food and Beverage, Manufacturing, Retail
- Stage:Seed, Series A, Convertible Note
- Geography: Israel
Investor stats
- Total investments: 17
- Round size: Seed $2.5M–$4.1M; Series A $3.5M–$15M; Convertible Note $4M–$10M
- Lead/follow: 65% lead, 35% follow
Portfolio highlights
- TripleW Group NV — Making Waste History. TripleW upcycles food waste into high-value bioplastic
- ansā — Objectively Awesome Coffee
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
Accelmed is a venture capital firm that funds private and public medical device companies with significant market potential and proven clinical data.Concentrating on medical device companies that have already reached the revenue stage enables the firm to assist companies in benefiting from its managerial capabilities and financial resources.Together with the management teams of their portfolio companies, the Accelmed can steer the way from the clinical-stage to a profitable business with a clear commercial plan, thereby accelerating the path to a successful exit.In 2009, Mori Arkin and Uri Geiger, the co-founders of Accelmed, established the firm in Herzliya, Tel Aviv.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Series D, Series A
- Geography: Israel, United States
Investor stats
- Total investments: 37
- Round size: Series A $695k–$24M; Series D $13M–$96M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Corvia Medical — Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts.
- UltraClear —
- GT Medical Technologies — GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement.
Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech.With two offices in Israel, Pitango currently managesseveral venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Series B, Series C
- Geography: Israel, United States, China
Investor stats
- Total investments: 281
- Round size: Series A $4M–$50M; Series B $7.5M–$44M; Series C $8.2M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $175M in 2023
Portfolio highlights
- Convizit — Convizit's AI automatically captures user actions, adds properties, and delivers this behavioral data directly into your analytics and marketing platforms.
- Tomorrow.io — Predict, automate, and solve your biggest weather challenges with Tomorrow.io.
- DriveNets — Providing the highest performance Ethernet-based back-end network solutions for AI infrastructures and open, high-scale routing solutions for service providers
RMGP Biopharma Investment Fund is an investment Fund
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Health Care
- Stage:Seed, Series B
- Geography: Israel
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Ramino Bio — Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around.
- Pi Therapeutics — Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and hasoperated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.
- Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
Bits x Bites is a food tech VC that invests in early-stage startups tackling global food system challenges. It targets companies innovating across the food supply chain, from farming, production, distribution, and logistics, to consumer goods and food services.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Food Processing
- Stage:Series A, Seed, Series B
- Geography: China, Israel, Singapore
Investor stats
- Total investments: 28
- Round size: Seed $4k–$20M; Series A $917k–$100M; Series B $29M–$347M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $100M in 2020
Portfolio highlights
- Cataya Bio — Cataya Bio (Shanghai) Co., Ltd. is a product company powered by an advanced engineering biology platform and biomanufacturing. We engineer microbes and develop clean fermentation processes to manufacture products of high purity, at low cost, and in a sustainable way. We strive to help the world to transition away from petroleum and addressimportant global issues in environmental preservation, carbon emission and climate change.
- Ketai Bio — Ketai Bio is a synthetic biology company dedicated to the R&D, production and sales of high value-added bio-based products.
- Changjin Biotechnology — Changjin Biotechnology engages in the research, development, and industrialization of microbial synthetic proteins.
Bridges Israel is an impact investment fund which invests in Israeli businesses to generate competitive financial returns alongside significant measurable social impact. We are an independent affiliate of Bridges Fund Management.
Show more...Investment focus
- Industry: Agriculture, Health Care, Internet of Things
- Stage:Series A, Series B
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 20
- Round size: Series A $2.2M–$40M; Series B $8M–$60M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- N-Drip — A disruptive technology that provides precise irrigation, produces higher yields while saving water, without adding energy or needing water filtration.
- XRHealth — XRHealth is a medical device company that develops XR (VR\AR) therapeutic platform. The XRHealth Platform combines medical applications with advanced data analytics and remote monitoring, providing a comprehensive solution for clinicians and patients and pharma companies. The XRHealth Platform collects and analyzes patient interactions withvirtual objects in virtual environments. AI cloud computing algorithms let us deliver an enhanced experience and real-time data analytics that can be used in clinics and in the home. With our technology, patients can analyze and quantify their own performance and track their own improvement over time.XRHealth is the first Certified Virtual Reality (VR) Medical Company to develop FDA/CE Registered Medical Applications. Our products focus on motor, cognitive, physical, psychological, postural ability and pain assessment and treatment.
- Kando — Kando is an end-to-end solution that creates continuous awareness of events in the collection system. Kando enables utilities to remotely and continuously improve their operations by providing the following features:• Realtime wastewater quality data across the collection system • Pinpoint sources of pollution • Early warnings of damaging WWTPinfluent quality • Machine learning that evolves with your network • Autonomous sampling units • User fee calculator • Customized pollution alerts • A user-friendly, online interface • Detection of COVID-19 infection rates (New)The combination of these actionable insights results in:• Reduced CAPEX/OPEX • Greater WW reuse capabilities • Improved public health • Cleaner environmentsKando has been deployed in Los Angeles, Milan, Brisbane, and many other cities. To gain a greater understanding of how our system can help your organization, visit our homepage at www.kando.eco.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Impact First Investments is the first Israeli impact venture capital fund with the trifold aim to bolster Israeli technology, to build global social impact, and to obtain market-rate returns.Impact investing is dynamic. It’s a web of enterprise, venture, and ingenuity with the goal to do good and do well. At Impact First, they capitalize onboldness.Technology has the ability to both address challenges and scale solutions. They capitalize and advance this interest. They recognize this growing potential of doing good and doing well, and combined with experience in Israeli high tech, they have the ability to address global social challenges by supporting social tech startups.
Show more...Investment focus
- Industry: Health Care, mHealth, Medical Device
- Stage:Seed, Series A
- Geography: Israel, United States
Investor stats
- Total investments: 5
- Round size: Seed $500k–$8M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- MyndYou — The Care Orchestration Platform that unites healthcare.
- EyeControl — EyeControl is a medical technology company specializing in innovative communication solutions. We implement advanced AI-technologies to bridge information barriers, facilitating better care and decision-making in healthcare environments.
- General Galactic — General Galactic revolutionize the energy supply chain by producing synthetic hydrocarbons from air and waste CO2 using renewable electricity, making clean fuel affordable and accessible. General Galactic is developing technology to enable democratization of access to critical fuels at the site of need through modular hardware.
We are an early stage venture capital fund passionate about helping entrepreneurs bring innovative solutions to market.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A
- Geography: United States, Israel, Australia
Investor stats
- Total investments: 60
- Round size: Seed $1M–$8M; Series A $2M–$14M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- memQ — memQ blends quantum science, materials, and photonics to create the first extensible quantum network architecture for industry, research, and government.
- SkyHoop — SkyHoop is a technology startup that develops software for defense systems.
- Marketeam.ai — Marketeam.ai is a GenAI startup that has developed the first proprietary Foundation Language Model for marketing (FLM, DALM), and is training autonomous AI agents to work collaboratively with humans as a marketing team to manage business' marketing end-to-end.Marketeam.ai empowers every business to have its own 'pro marketing team'working together 24/7 on building, promoting, and managing their brand to accelerate growth with expert-level skills, at platform-level cost & speed. The platform offers autonomous AI marketing agents, combining expert strategy and 24/7 operational efficiency. Ideal for businesses aiming to enhance ROI and growth with a cutting-edge AI marketing team.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 171
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
- ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Tyson Ventures is the investment arm of Tyson Foods. We aim to be the strategic partner of choice for disruptive innovators transforming the food industry, and provide sustainable nutrition to a growing global population. Our current areas of interest focus on emerging proteins, technology enablers and sustainability. Let’s build the future offood... together.
Show more...Investment focus
- Industry: Food and Beverage, Biotechnology, Software
- Stage:Grant, Series A
- Geography: United States, Israel
Investor stats
- Total investments: 33
- Round size: Series A $4M–$37M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $150M in 2016
Portfolio highlights
- Athian — Funding livestock sustainability via a connected carbon marketplace.
- Orderful — Gain full control to onboard, manage and resolve all of your EDI trading partner relationships and transactions in real-time.
- Oxipital AI — On August 6, 2024, Soft Robotics Inc. announced the divestiture of its gripper business assets to the Schmalz Group, a move that will allow both companies to focus on advancements in Vision Inspection and Defect Detection technologies, including the integration of Oxipital AI.
CE Ventures was established in 2015 to focus on investments in private technology companies located in Israel and the United States. It considers opportunities across a broad spectrum of industries, including technology, media, telecommunications and digital health and invests in a mixture of early and later-stage opportunities.
Show more...Investment focus
- Industry: Software, Analytics, Big Data
- Stage:Series B, Series A, Series C
- Geography: Israel, United States, India
Investor stats
- Total investments: 34
- Round size: Series A $4M–$7M; Series B $4M–$30M; Series C $10M–$40M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- DiA Imaging Analysis — DiA is the leading provider of FDA cleared and CE marked ultrasound AI solutions that make the use and analysis of ultrasound images smarter, faster and accessible to all. Our solutions address the main challenges ultrasound users face - manually capturing and visually analyzing ultrasound images.
- NirogStreet — NirogStreet is the best platform for Ayurveda doctors. Learn and Earn from top Ayurveda Experts and get authentic Ayurvedic medicines at the best deals.
- Centrical — Centrical helps businesses improve employee engagement, proficiency, and performance through gamification, microlearning, and performance management.
Arancia International Inc is a part of Arancia Group in Mexico. We are long term investors in food, nutrition and biotechnology companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Series A, Series B
- Geography: Israel, United States, Malaysia
Investor stats
- Total investments: 9
- Lead/follow: no public data
Portfolio highlights
- NextFerm — NextFerm is a science oriented industrial company, representing a new era in fermentation and fermentation-derived nutrients for supplements, food, infant nutrition and animal feed.The world is striving for better nutrition. Nutrition which is less artificial and more natural, sustainable and cost effective - with a much higher nutritional value.At Nextferm, they aim to use their capabilities to lead this new and exciting world of better nutrition.
- iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
- The Mediterranean Food Lab — The Mediterranean Food Lab merge traditional fermentation and cutting-edge science, to produce natural plant-based flavor-bases for a wide range of meat replacement needs.
PeakBridge is a highly networked, global impact VC that funds and connects the people, technology and processes that will shape the future of food. We invest in visionary pioneers, from early stage to Series A-B, with scalable, protectable climate and health-focused technologies. At their core: a deep commitment to disrupting our food system whiledriving positive impact. Our team is spread across seven countries and includes pioneers of FoodTech investment and decades of deep Agri-Food operational and financial experience. Together, we create exceptional value for bold FoodTech entrepreneurs and investors. A member of the Edmond de Rothschild Private Equity partnership, PeakBridge is also the only venture capital firm that is an official partner of the world’s largest Agri-Food innovation initiative, EIT Food.
Show more...Investment focus
- Industry: Food and Beverage, Health Care, Food Processing
- Stage:Series A, Seed, Series B
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 51
- Round size: Seed $571k–$11M; Series A $4.5M–$17M; Series B $11M–$50M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $106M in 2022
Portfolio highlights
- Myota — Myota is a science and tech-based platform that develops fiber-based microbiome interventions to treat and prevent chronic disease. Myota was founded in 2019 and was headquartered in London, England.
- Ilant Health — We offer a comprehensive solution that take the stress and stigma out of obesity treatment. We increase access, improve quality, and drive reduction in total cost of care.
- KÄÄPÄ Biotech — Medicinal mushrooms, biotechnology, mycology, forestry, agroforestry, and food production.
Flerie is an active long-term life science investor, focusing on biotech and pharmaceutical investments globally.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Sweden, Israel, Iceland
Investor stats
- Total investments: 13
- Lead/follow: no public data
Portfolio highlights
- AnaCardio — AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
- XNK Therapeutics — XNK Therapeutics, founded in 2012, is one of the pioneering companies within the landscape of cell therapy.
- Vitara Biomedical — Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care.
Yozma earned worldwide recognition as the founder of Israel's VC industry.
Show more...Investment focus
- Industry: Health Care, Medical, Software
- Stage:Series B, Seed
- Geography: Israel, United States, Australia
Investor stats
- Total investments: 23
- Lead/follow: no public data
Portfolio highlights
- OP.GG — The Best LoL Champion Builds and Player Stats by OP.GG - Learn champion builds, runes, and counters. Search Riot ID and Tagline for stats of all game modes.
- Illumigyn — Technology that we developed, creating high-resolution digital images with superior magnification that can substantially improve diagnostic accuracy.
- Meat.The End — MTE revolutionizes food production to create desired textures and provides a solution for food companies, by developing novel ingredients and technological solutions that enhance the texture properties of alternative protein products.
Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Post-IPO Equity, Series A, Corporate Round
- Geography: United States, Israel, France
Investor stats
- Total investments: 51
- Lead/follow: no public data
Portfolio highlights
- CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
- AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
- EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.
Biotechnology VC funding in Israel at a glance
Stats across 557 deals from 628 investors.
Access all 628 VC funds in Israel Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology VC Funds in Israel investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 628 VC funds investing in Israel Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!